ClinicalTrials.gg
RecruitingNCT06870903ENDONOTEUpdated Mar 20, 2025

Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surgery for Patients Diagnosed With Endometrial Cancer

An interventional study of Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy and Transperitoneal lymphadenectomy in Endometrial Cancer, Lymphadenectomy and Sentinel Lymph Node Biopsy, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Endometrial Neoplasms with a site in Turkey — 14 open to participants now, 18 under way, 4 of them phase 3. Endometrial Neoplasms · Turkey.

Planned enrollment
28th of 33
52 · median 100
Started
2025
with 6 others
No phase
18 of 46
6 open now
Primary completion
2025-12
later than 3 of 17 live
Registered
35th of 46
by date
Lead sponsor
2 of 46
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Among the 46 studies in Endometrial Neoplasms with a site in Turkey, this one is the 28th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 3 of the 17 other live ones, and was the 35th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

14 of the 46 studies in Endometrial Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Endometrial Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.

Read the detailed description

Surgical staging is often the primary management strategy for endometrial cancer. Sentinel lymph node (SLN) procedures are considered an alternative standard of care in the treatment of significant uterus-confined malignancy. Both accurately estimate nodal status and reduce the surgical morbidity associated with complete lymphadenectomy. Laparoscopic surgery for endometrial cancer has been associated with equal or better quality of life, less blood loss and similar cancer-related outcomes. A new innovation, natural orifice transluminal endoscopic surgery (NOTES), has been developed to further reduce morbidity and scarring associated with laparoscopic surgery. NOTES utilizes the natural orifices of the human body for access to the peritoneal cavity when performing endoscopic surgery.

However, there is no standardization in vNOTES SLN mapping and lymph tracers are diverse. Many procedures and tracers have been reported, such as intra- or retroperitoneal surgery, a range of vaginal surgeries, SLN exposure method, and indocyanine green or methylene blue injection, and they lack comparative studies. This study will evaluate feasibility and surgical outcomes by comparing transvaginal paracervical and transperitoneal mapping in vNOTES hysterectomy with SLN procedure in endometrial cancer.

The study is an observational study with a prospective design. It will be implemented in a single institution, specifically Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.

Between March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping.

According to inclusion and exclusion criteria, the patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group.

Surgical Procedure of transvaginal paracervical sentinel lymphadenectomy group:

All patients(26) will receive V-NOTES with transvaginal paracervical sentinel lymph node (SLN) mapping followed by V-NOTES hysterectomy and bilateral salpingo-oophorectomy (BSO).

Transperitoneal sentinel lenfadenectomy group's Surgical Procedure:

All patients (26) will receive vNOTES hysterectomy with bilateral salpingo-oophorectomy (BSO) followed by transperitoneal vNOTES sentinel lymph node (SLN) mapping.

03

Conditions studied

  • Endometrial Cancer
  • Lymphadenectomy
  • Sentinel Lymph Node Biopsy
  • Minimally Invasive Surgical Procedures
  • Natural Orifice Transluminal Endoscopic Surgery

Keywords

  • endometrial cancer
  • V-NOTES
  • lymphadenectomy
  • sentinel lymph node
  • transperitoneal
  • extraperitoneal
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patient Selection and Data Collection This study will be implemented in a single institution, Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.

Between March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping at our institution will be randomized into groups. The research procedure has been approved by the ethics committee/institutional review board of Diyarbakır Gazi Yaşargil Training and Research Hospital and signed by the patient will be included in each table reviewed.

Eligible participants will be required to give informed consent to participate in the study.

Inclusion criteria

Inclusion criteria will include

  • Participants whose endometrial resulted in endometrial cancer and whose disease will be detected limited to the uterus using imaging modalities (computed tomography [CT], magnetic resonance imaging or Fluorine-18 fluorodeoxyglucose positron emission tomography/CT)
  • Absence of synchronous .
  • No treatment before surgical intervention.

Exclusion criteria

Exclusion criteria will include:

  • to using methylene blue dye or contraindications to the vNOTES procedure.
  • Patients who have had previous surgery.
  • Severe, deeply penetrating endometriosis or enlarged uterus that may require forced vaginal extraction
  • Receiving neodajuvant therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    transvaginal paracervical sentinel lymphadenectomy group

    Surgical Procedure of transvaginal sentinel lymphadenectomy group: All patients will be operated in accordance with Memorial Sloan Kettering Cancer Center procedure. V-NOTES will consist of transvaginal paracervical sentinel lymph node (SLN) mapping followed by V-NOTES hysterectomy and bilateral salpingo-oophorectomy (BSO). SLN Mapping: Under general anesthesia, subjects will be placed in supine lithotomy position. Methylene blue solution (BLUMET IV INJECTION INJECTABLE 50 mg/5 ml 1x5 ml) (1 mL submucosal to the cervix at the 3 and 9 o'clock positions and 1 mL at a depth of 1-2 cm, using a total volume of 2-4 mL. Monitoring of lymphatic ducts includes identification of structures stained with methylene blue dye in the expected anatomical location, typically between the internal and external iliac veins or in the obturator region. Bilateral and symmetrical structures believed to be sentinel lymph nodes (SLNs) will be removed. When unilate

    Procedure: Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy

  • Active comparator
    Transperitoneal lymphadenectomy

    In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with methylene blue injection for sentinel lymph nodes. Methylene blue will be injected at the 3 and 9 o'clock positions on the cervix, first at a depth of 1 mm and then at 4 mm, with 1 cc administered at each point. This will result in a total of 4 cc (1 cc x 4). Then, the procedure will continue with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.

    Procedure: Transperitoneal lymphadenectomy

Interventions

  • ProcedureExtraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy

    The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).

  • ProcedureTransperitoneal lymphadenectomy

    In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.

06

What researchers measure

Primary outcomes

  1. Total operation duration

    The total duration of the operation in minutes

    Time frame: During surgery

  2. Duration of right and left lymphadenectomy

    The duration of lymphadenectomies in minutes

    Time frame: During surgery

  3. Number of lymph nodes excised

    Lymph node count in the pathology report

    Time frame: Postoperative second week

  4. number of positive lymph nodes

    Sentinel positive lymph nodes in the pathology report

    Time frame: Postoperative second week

  5. Hospitalization duration

    Number of days patients stayed at the hospital postoperatively

    Time frame: During hospital stay

  6. Total bleeding volume

    Measured by the suction bottle's volume and number of surgical gauzse used during surgery

    Time frame: During surgery

  7. Difference between pre- and postoperative hemoglobin values

    Hemoglobin level (g/dL)

    Time frame: Postoperative 1st day

  8. Surgical complications

    Clavien dindo scale of surgical complications

    Time frame: During hospital stay

  9. Location o SLN

    The area that sentinel lymph node detected internal iliac, external iliac ,bifurcation or obturator fossa

    Time frame: During surgery

  10. Preoperative and postoperative hematocrit values

    Hematocrit level (%)

    Time frame: During hospital stay

  11. Tumor's patological features

    Histophatology, grade, lymphovascular invasion, tumor diameter(cm), myometrial invasion, stage, total positive lymph node count

    Time frame: Postoperative second week

  12. Management of complications

    intraoperative and postoperative complication's management

    Time frame: through study completion

  13. Duration of lateral colpotomy

    at transvaginal retroperitoneal procedure ; before the lymphadenectomy we are making and incision to the lateral of cervix .this time describes the time that to reach the obturator fossa to pick the nodes.

    Time frame: During surgery

  14. Duration of hysterectomy

    minutes

    Time frame: During surgery

  15. Sentinel lymphnode's side and number

    number

    Time frame: Postoperative second week

Secondary outcomes

  1. Postoperative pain

    visual analogue scale, higher scores indicate worse pain

    Time frame: 3rd and 6th month after operation

  2. Sexual function

    assessed by Female Sexual Function Index, higher scores indicate greater satisfaction

    Time frame: at postoperative 3rd and 6th month

  3. Timing of passing gas

    Bowel function

    Time frame: During hospital stay

  4. Demographic features

    Age, gravidity, parity, previous vaginal delivery, body-mass index

    Time frame: Postoperative second week

  5. Previous abdominal surgery

    Medical history

    Time frame: Preoperative day

  6. Initiation of mobilization

    After operation the time (hour) that paient is avaliable to mobilize out from the bed

    Time frame: During hospital stay

  7. 6th hour and 24th hour VAS score

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."

    Time frame: postoperatively 6th and 24th hours score

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Deng L, Liu Y, Yao Y, Deng Y, Tang S, Sun L, Wang Y. Efficacy of vaginal natural orifice transluminal endoscopic sentinel lymph node biopsy for endometrial cancer: a prospective multicenter cohort study. Int J Surg. 2023 Oct 1;109(10):2996-3002. doi: 10.1097/JS9.0000000000000551. PubMed 37335988 ↗
  • Can B, Akgol S, Adiguzel O, Kaya C. A new, less invasive approach for retroperitoneal pelvic and para-aortic lymphadenectomy combining the transvaginal natural orifice transluminal endoscopic surgery (vNOTES) technique and single-port laparoscopy. Int J Gynecol Cancer. 2024 May 6;34(5):789-790. doi: 10.1136/ijgc-2023-005093. No abstract available. PubMed 38316443 ↗
  • Baekelandt J, Jespers A, Huber D, Badiglian-Filho L, Stuart A, Chuang L, Ali O, Burnett A. vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter, prospective case series. Acta Obstet Gynecol Scand. 2024 Jul;103(7):1311-1317. doi: 10.1111/aogs.14843. Epub 2024 Apr 16. PubMed 38623778 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: It will be shared when the study is published.

Access criteria: When the study is published, the data will be shared by the corresponding author on request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 9 months is below that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 11, 2025
StartActual
Mar 15, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 1, 2026
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870903
Lead sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Responsible party
Sedat Akgöl (Head of Gynecology Oncology Department, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital) — Principal investigator
First posted
Mar 11, 2025
Start date
Mar 15, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Mar 20, 2025

Study contacts

Kevser Arkan, MD
Contact
kevser.toprak1989@gmail.com
+905536476838
Behzat Can, Assoc. Prof.
study chair · Health Sciences University Gazi Yasargil Training and Research Hospital
Sedat Akgol, Assoc. Prof.
study director · Health Sciences University Gazi Yasargil Training and Research Hospital
Kevser Arkan, MD
principal investigator · Health Sciences University Gazi Yasargil Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion